Opportunity Information: Apply for RFA DK 16 011

  • The HHS-NIH11 in the food and nutrition, health sector is offering a public funding opportunity titled "Standardization of C-peptide and HbA1c Measurements Program (UC4)" and is now available to receive applicants.
  • Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.847,.
  • This funding opportunity was created on May 23, 2016 and posted on May 23, 2016.
  • Applicants must submit their applications by Nov 22, 2016. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
  • Each selected applicant is eligible to receive up to $350,000.00 in funding.
  • The number of recipients for this funding is limited to 1 candidate(s).
  • Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For profit organizations other than small businesses, Small businesses, Others (see text field entitled Additional Information on Eligibility for clarification).
Apply for RFA DK 16 011

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:

Opportunity Summary:

The "Standardization of C-peptide and HbA1c Measurements Program (UC4)" grant opportunity (RFA DK 16 011) is a National Institutes of Health (NIH) funding announcement under HHS (listed as HHS-NIH11) focused on improving the consistency and comparability of two key laboratory measurements used in type 1 diabetes clinical research: C-peptide and HbA1c. The core purpose is to support harmonization and standardization efforts so that results generated across different clinical laboratories, studies, and testing platforms can be compared more reliably. This matters because even small differences in lab methods, reagents, or calibration approaches can lead to measurement variability that complicates clinical trial interpretation, cross-study comparisons, and longitudinal tracking of biomarkers.

The funding is structured as a cooperative agreement (UC4), meaning the project is expected to involve substantial interaction and coordination with the NIH rather than operating purely as an investigator-directed research grant. The FOA seeks applications to establish a Central Primary Reference Laboratory (CPRL). In practical terms, the CPRL functions as the central hub that anchors measurement standardization: it is expected to coordinate laboratories and stakeholders, manage the operational and administrative pieces of harmonization, and provide reference-level measurement services that others can align to.

A major part of the CPRL role described in the announcement is administrative and coordinating work. The laboratory is expected to bring together clinical laboratories involved in type 1 diabetes research and also engage commercial suppliers whose reagents and measurement methods influence how C-peptide and HbA1c are quantified. This coordination piece is important because standardization is not only a technical laboratory task; it often requires agreement on protocols, calibration materials, traceability chains, quality assurance practices, data reporting conventions, and processes for handling method changes over time. The FOA indicates the CPRL will help organize and support these harmonization activities across the relevant ecosystem.

Alongside coordination, the CPRL is also expected to perform measurements of reference values specifically for C-peptide and HbA1c. In a standardization framework, reference values serve as the benchmark needed to align results from multiple sites and methods. By producing high-quality reference measurements, the CPRL helps ensure that participating labs and studies can calibrate or validate their own assays against a consistent standard, reducing systematic differences and improving the overall interpretability of clinical research data in type 1 diabetes.

From an administrative standpoint, the opportunity falls under the "Discretionary" category and the activity category of "Food and Nutrition, Health," with CFDA numbers 93.847 and related listings. The FOA is open to a broad range of applicant organizations, including federal recognized tribal governments and tribal organizations, state and local governments, public and private institutions of higher education, nonprofit organizations (both 501(c)(3) and non-501(c)(3)), for-profit organizations (including small businesses), and other entities as permitted in the announcement's eligibility clarification. This wide eligibility signals that NIH is primarily looking for the best-qualified organization to serve as the central reference laboratory, regardless of whether it sits in academia, government, nonprofit, or industry, as long as it can meet the technical and coordination demands.

In terms of funding and scale, the award ceiling is listed as $350,000, with an expectation of one award. That points to a single centralized awardee model, where one CPRL is selected to lead and deliver the reference laboratory and harmonization support functions for the program. Key dates provided show the FOA was created and posted on May 23, 2016, with an application closing date of November 22, 2016 (original and current closing dates are the same), indicating it was a time-limited solicitation with a defined submission window.

Overall, this opportunity is essentially about building the measurement backbone for type 1 diabetes research by selecting one central laboratory to coordinate stakeholders and produce reference measurements for C-peptide and HbA1c. The intended outcome is better standardization across studies and sites, improving confidence that biomarker results mean the same thing regardless of where or how they were measured, which in turn strengthens clinical trial quality and the ability to compare findings across research efforts.

Frequently Asked Questions (FAQs)

What is the "Standardization of C-peptide and HbA1c Measurements Program (UC4)" funding opportunity?

It is an NIH funding announcement under HHS (listed as HHS-NIH11), identified as RFA DK 16 011. The opportunity supports a program focused on improving the consistency and comparability of two laboratory measurements used in type 1 diabetes clinical research: C-peptide and HbA1c.

What is the main goal of this program?

The main goal is harmonization and standardization of C-peptide and HbA1c measurements so results produced across different clinical laboratories, studies, and testing platforms can be compared more reliably.

Why does standardization of C-peptide and HbA1c matter in type 1 diabetes research?

Small differences in lab methods, reagents, or calibration approaches can create measurement variability. That variability can complicate clinical trial interpretation, cross-study comparisons, and longitudinal tracking of biomarkers. Standardization reduces systematic differences so biomarker results are more interpretable across sites and over time.

What type of award mechanism is used for this opportunity?

This opportunity uses a cooperative agreement mechanism (UC4), which indicates substantial interaction and coordination with NIH is expected, rather than a fully investigator-directed research grant structure.

What does a cooperative agreement (UC4) imply for how the project will be run?

A UC4 cooperative agreement means the awardee should expect substantial involvement, interaction, and coordination with NIH as part of carrying out the program activities described in the announcement.

What is the CPRL referenced in the announcement?

CPRL stands for Central Primary Reference Laboratory. The FOA seeks applications to establish a CPRL to serve as the central hub for measurement standardization activities for C-peptide and HbA1c within type 1 diabetes clinical research.

What is the intended role of the Central Primary Reference Laboratory (CPRL)?

The CPRL is expected to anchor standardization by coordinating laboratories and stakeholders, managing operational and administrative aspects of harmonization, and providing reference-level measurement services that other labs and studies can align to.

What kinds of coordination activities is the CPRL expected to perform?

The CPRL is expected to bring together clinical laboratories involved in type 1 diabetes research and engage commercial suppliers whose reagents and measurement methods influence how C-peptide and HbA1c are quantified. The CPRL helps organize and support harmonization activities across this ecosystem.

Is the CPRL role mainly technical lab work, or is it also administrative?

It includes both, with a major portion described as administrative and coordinating work. Standardization is presented as requiring stakeholder alignment and ongoing coordination, not only laboratory technique.

What kinds of issues does harmonization typically require agreement on, according to the announcement?

The announcement notes that harmonization often requires agreement on protocols, calibration materials, traceability chains, quality assurance practices, data reporting conventions, and processes for handling method changes over time.

What measurements is the CPRL expected to produce?

The CPRL is expected to perform measurements of reference values specifically for C-peptide and HbA1c.

What are "reference values" in the context of this program?

Reference values are benchmark measurements used to align results across multiple sites and methods. By producing high-quality reference measurements, the CPRL enables participating labs and studies to calibrate or validate their assays against a consistent standard.

How does producing reference measurements improve research comparability?

Reference measurements provide a consistent benchmark that reduces systematic differences among laboratories and platforms. This supports more reliable comparisons across clinical labs, studies, and timepoints within type 1 diabetes research.

Which agency is offering this opportunity?

The opportunity is offered under the National Institutes of Health (NIH) within HHS, and is listed as HHS-NIH11.

What is the funding category and activity category listed for this opportunity?

The opportunity falls under the "Discretionary" category and the activity category of "Food and Nutrition, Health."

What CFDA numbers are associated with this opportunity?

The announcement references CFDA number 93.847 and related listings.

Who is eligible to apply for this FOA?

The FOA is open to a broad range of applicant organizations, including: federally recognized tribal governments and tribal organizations; state and local governments; public and private institutions of higher education; nonprofit organizations (501(c)(3) and non-501(c)(3)); for-profit organizations (including small businesses); and other entities as permitted by the eligibility clarification in the announcement.

Does the opportunity limit awards to academic institutions only?

No. The eligibility described is broad and includes academic, government, nonprofit, and for-profit organizations, indicating the NIH is seeking the best-qualified organization to serve as the central reference laboratory, regardless of sector, as long as it can meet the technical and coordination demands.

How many awards are expected to be made?

The information provided indicates an expectation of one award, consistent with a single centralized awardee model for the CPRL.

What is the award ceiling for this opportunity?

The award ceiling is listed as $350,000.

When was the FOA created and posted?

The FOA was created and posted on May 23, 2016.

What was the application closing date?

The application closing date is listed as November 22, 2016, and the original and current closing dates are the same, indicating a defined submission window.

What is the overall intended outcome of the program?

The intended outcome is improved standardization across studies and sites so biomarker results for C-peptide and HbA1c mean the same thing regardless of where or how they were measured, strengthening clinical trial quality and cross-study comparability in type 1 diabetes research.

Browse more opportunities from the same agency: HHS-NIH11

Browse more opportunities from the same category: Food and Nutrition, Health

Next opportunity: BLM-ES, Jupiter Inlet Lighthouse ONA Biological Management Support

Previous opportunity: Glacier and perennial snowfield mass balance of Rocky Mountain National Park (ROMO): Historic, Modern and Future

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for RFA DK 16 011

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (RFA DK 16 011) also looked into and applied for these:

Funding Opportunity
Diabetes Research Centers (P30) Apply for RFA DK 16 020

Funding Number: RFA DK 16 020
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: Case Dependent
Ancillary Studies to Identify Behavioral and/or Psychological Phenotypes Contributing to Obesity (R01) Apply for PAR 16 304

Funding Number: PAR 16 304
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: Case Dependent
Limited Competition for the Continuation of the Collaborative Islet Transplantation Registry (UC4) Apply for RFA DK 16 503

Funding Number: RFA DK 16 503
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: Case Dependent
Neurocognitive Effects of Glycemic Dysregulation in Type 1 Diabetes (DP3) Apply for RFA DK 16 007

Funding Number: RFA DK 16 007
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: $3,000,000
Metabolic Contributions to the Neurocognitive Complications of Diabetes: Ancillary Studies (R01) Apply for PAR 16 333

Funding Number: PAR 16 333
Agency: HHS-NIH11
Category: Food and Nutrition, Health
Funding Amount: Case Dependent
Pediatric Centers of Excellence in Nephrology (P50) Apply for RFA DK 16 032

Funding Number: RFA DK 16 032
Agency: Department of Health and Human Services, National Institutes of Health
Category: Food and Nutrition, Health
Funding Amount: $750,000
George M. O'Brien Kidney Research Core Centers (P30) Apply for RFA DK 16 031

Funding Number: RFA DK 16 031
Agency: Department of Health and Human Services, National Institutes of Health
Category: Food and Nutrition, Health
Funding Amount: $750,000
Promoting Organ and Tissue Donation Among Diverse Populations (R01) Apply for RFA DK 16 022

Funding Number: RFA DK 16 022
Agency: Department of Health and Human Services, National Institutes of Health
Category: Food and Nutrition, Health
Funding Amount: $150,000
Limited Competition for Data Coordinating Center (DCC) for NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) (U24) Apply for RFA DK 16 510

Funding Number: RFA DK 16 510
Agency: Department of Health and Human Services, National Institutes of Health
Category: Food and Nutrition, Health
Funding Amount: $1,062,000
NIDDK Inflammatory Bowel Disease Genetics Consortium (IBDGC) Genetic Research Centers (GRCs) (U01) Apply for RFA DK 16 029

Funding Number: RFA DK 16 029
Agency: Department of Health and Human Services, National Institutes of Health
Category: Food and Nutrition, Health
Funding Amount: $293,000
Coordinating Unit for the Mouse Metabolic Phenotyping Centers (U24) Apply for RFA DK 16 034

Funding Number: RFA DK 16 034
Agency: Department of Health and Human Services, National Institutes of Health
Category: Food and Nutrition, Health
Funding Amount: $1,212,563
Coordinating Unit for Diabetic Complications Consortium (U24) Apply for RFA DK 16 036

Funding Number: RFA DK 16 036
Agency: Department of Health and Human Services, National Institutes of Health
Category: Food and Nutrition, Health
Funding Amount: $3,122,000
APOL1 Long-term Kidney Transplantation Outcomes Network Scientific and Data Research Center (APOLLO SDRC) (Collaborative U01) Apply for RFA DK 16 024

Funding Number: RFA DK 16 024
Agency: Department of Health and Human Services, National Institutes of Health
Category: Food and Nutrition, Health
Funding Amount: $500,000
Limited Competition: Data Coordinating Center for Type 1 Diabetes TrialNet (UC4) Apply for RFA DK 16 505

Funding Number: RFA DK 16 505
Agency: Department of Health and Human Services, National Institutes of Health
Category: Food and Nutrition, Health
Funding Amount: $45,000,000
Limited Competition: Revision Application for the Human Islet Research Network Coordinating Center (U01) Apply for RFA DK 17 501

Funding Number: RFA DK 17 501
Agency: Department of Health and Human Services, National Institutes of Health
Category: Food and Nutrition, Health
Funding Amount: $4,737,500
Developmental Centers for Interdisciplinary Research in Benign Urology (P20) Apply for RFA DK 17 002

Funding Number: RFA DK 17 002
Agency: Department of Health and Human Services, National Institutes of Health
Category: Food and Nutrition, Health
Funding Amount: $200,000
George M. O'Brien Kidney Research Core Centers (P30) Apply for RFA DK 17 005

Funding Number: RFA DK 17 005
Agency: Department of Health and Human Services, National Institutes of Health
Category: Food and Nutrition, Health
Funding Amount: $750,000
Limited Competition: Follow-up on Subjects and Immunological Assessments in The Environmental Determinants of Diabetes In The Young Study (TEDDY) (UC4) Apply for RFA DK 17 508

Funding Number: RFA DK 17 508
Agency: Department of Health and Human Services, National Institutes of Health
Category: Food and Nutrition, Health
Funding Amount: $27,000,000
Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (U24) Apply for RFA HL 17 028

Funding Number: RFA HL 17 028
Agency: Department of Health and Human Services, National Institutes of Health
Category: Food and Nutrition, Health
Funding Amount: $3,245,000
Revision Applications for Regenerative Medicine Innovation Projects (RMIP) (UM2) Apply for RFA HL 17 031

Funding Number: RFA HL 17 031
Agency: Department of Health and Human Services, National Institutes of Health
Category: Food and Nutrition, Health
Funding Amount: $324,500

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

USGrants.org applicant portal membership

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "RFA DK 16 011", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.